137 related articles for article (PubMed ID: 17066424)
1. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector.
Takei Y; Mizukami H; Saga Y; Yoshimura I; Hasumi Y; Takayama T; Kohno T; Matsushita T; Okada T; Kume A; Suzuki M; Ozawa K
Int J Cancer; 2007 Jan; 120(2):278-84. PubMed ID: 17066424
[TBL] [Abstract][Full Text] [Related]
2. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer.
Hasumi Y; Mizukami H; Urabe M; Kohno T; Takeuchi K; Kume A; Momoeda M; Yoshikawa H; Tsuruo T; Shibuya M; Taketani Y; Ozawa K
Cancer Res; 2002 Apr; 62(7):2019-23. PubMed ID: 11929819
[TBL] [Abstract][Full Text] [Related]
3. Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo.
Ramachandra S; D'Souza SS; Gururaj AE; Shaila MS; Salimath BP
J Gene Med; 2009 May; 11(5):422-34. PubMed ID: 19266483
[TBL] [Abstract][Full Text] [Related]
4. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity.
Mahasreshti PJ; Kataram M; Wang MH; Stockard CR; Grizzle WE; Carey D; Siegal GP; Haisma HJ; Alvarez RD; Curiel DT
Clin Cancer Res; 2003 Jul; 9(7):2701-10. PubMed ID: 12855650
[TBL] [Abstract][Full Text] [Related]
5. sFlt-1 gene therapy of follicular thyroid carcinoma.
Ye C; Feng C; Wang S; Wang KZ; Huang N; Liu X; Lin Y; Li M
Endocrinology; 2004 Feb; 145(2):817-22. PubMed ID: 14605010
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
Mahendra G; Kumar S; Isayeva T; Mahasreshti PJ; Curiel DT; Stockardt CR; Grizzle WE; Alapati V; Singh R; Siegal GP; Meleth S; Ponnazhagan S
Cancer Gene Ther; 2005 Jan; 12(1):26-34. PubMed ID: 15359287
[TBL] [Abstract][Full Text] [Related]
7. Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factors.
Takahashi Y; Saga Y; Koyanagi T; Takei Y; Machida S; Taneichi A; Mizukami H; Sato Y; Matsubara S; Fujiwara H
Cancer Sci; 2016 May; 107(5):629-37. PubMed ID: 26893100
[TBL] [Abstract][Full Text] [Related]
8. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1.
Zhang Z; Zou W; Wang J; Gu J; Dang Y; Li B; Zhao L; Qian C; Qian Q; Liu X
Mol Ther; 2005 Apr; 11(4):553-62. PubMed ID: 15771958
[TBL] [Abstract][Full Text] [Related]
9. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma.
Mahasreshti PJ; Navarro JG; Kataram M; Wang MH; Carey D; Siegal GP; Barnes MN; Nettelbeck DM; Alvarez RD; Hemminki A; Curiel DT
Clin Cancer Res; 2001 Jul; 7(7):2057-66. PubMed ID: 11448924
[TBL] [Abstract][Full Text] [Related]
11. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.
Davidoff AM; Nathwani AC; Spurbeck WW; Ng CY; Zhou J; Vanin EF
Cancer Res; 2002 Jun; 62(11):3077-83. PubMed ID: 12036917
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model.
Hu M; Yang JL; Teng H; Jia YQ; Wang R; Zhang XW; Wu Y; Luo Y; Chen XC; Zhang R; Tian L; Zhao X; Wei YQ
BMC Cancer; 2008 Oct; 8():306. PubMed ID: 18947384
[TBL] [Abstract][Full Text] [Related]
13. Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
Sallinen H; Anttila M; Gröhn O; Koponen J; Hämäläinen K; Kholova I; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Cancer Gene Ther; 2011 Feb; 18(2):100-9. PubMed ID: 20865022
[TBL] [Abstract][Full Text] [Related]
14. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.
Kosugi T; Nakayama T; Li Q; Chiodo VA; Zhang L; Campbell-Thompson M; Grant M; Croker BP; Nakagawa T
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F609-16. PubMed ID: 20015944
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated vector (type 8)-mediated expression of soluble Flt-1 efficiently inhibits neovascularization in a murine choroidal neovascularization model.
Igarashi T; Miyake K; Masuda I; Takahashi H; Shimada T
Hum Gene Ther; 2010 May; 21(5):631-7. PubMed ID: 20053138
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.
Kohno T; Mizukami H; Suzuki M; Saga Y; Takei Y; Shimpo M; Matsushita T; Okada T; Hanazono Y; Kume A; Sato I; Ozawa K
Cancer Res; 2003 Aug; 63(16):5091-4. PubMed ID: 12941839
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and soluble FLT-1 receptor interactions and biological implications.
Malecki M; Trembacz H; Szaniawska B; Przybyszewska M; Janik P
Oncol Rep; 2005 Dec; 14(6):1565-9. PubMed ID: 16273257
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys.
Lai CM; Shen WY; Brankov M; Lai YK; Barnett NL; Lee SY; Yeo IY; Mathur R; Ho JE; Pineda P; Barathi A; Ang CL; Constable IJ; Rakoczy EP
Mol Ther; 2005 Oct; 12(4):659-68. PubMed ID: 16023893
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice.
Subramanian IV; Ghebre R; Ramakrishnan S
Gene Ther; 2005 Jan; 12(1):30-8. PubMed ID: 15550927
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates.
Lai CM; Estcourt MJ; Himbeck RP; Lee SY; Yew-San Yeo I; Luu C; Loh BK; Lee MW; Barathi A; Villano J; Ang CL; van der Most RG; Constable IJ; Dismuke D; Samulski RJ; Degli-Esposti MA; Rakoczy EP
Gene Ther; 2012 Oct; 19(10):999-1009. PubMed ID: 22071974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
